Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China

Hepatology

Volumn 36, Issue 5 5 II, 2002, Pages 1214-1220

  Ming, Lihua ^a   Thorgeirsson, Snorri S ^b   Gail, Mitchell H ^c   Lu, Peixin ^d   Harris, Curtis C ^b   Wang, Nengjin ^d   Shao, Yongfu ^a   Wu, Zhiyuan ^a   Liu, Guoting ^a   Wang, Xiaohong ^a   Sun, Zongtang ^a  

^a CANCER HOSPITAL   (China)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NIH   (China)

^d QIDONG LIVER CANCER INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; AFLATOXIN B1; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; PROTEIN P53; SERINE;

ADULT; ANTIGEN DETECTION; ARTICLE; CANCER INCIDENCE; CHINA; CHRONIC HEPATITIS; DOSE RESPONSE; FEMALE; FOLLOW UP; GENDER; GENE MUTATION; GENE SEQUENCE; GENETIC RISK; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; LIVER CARCINOGENESIS; LIVER CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; VIRUS INFECTION;

EID: 0036828782     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.36366     Document Type: Article

References (35)

1. Li LD, Lu FZ, Zhang SW, Mu R, Sun ST, Huangfu XM. Distribution analysis of cancer mortality in China during 1990-1992. Chin J Oncol 1996;18:403-407.
2. Sun ZT, Ming LH, Zhu X, Lu JH. Prevention and control of hepatitis B in China. J Med Virol 2002;67:447-450.
3. Xia QJ, Li TS, Li YS, Sun ZT, Wang NJ, Shao LQ, Zhang SP. Liver cell cancer in young adolescent and its relation to hepatitis B virus. Chin J Oncol 1984;6:413-416.
4. Brechot C, Dogos F, Lugassy C, Thiers V, Zafrani S, Franco D, Bismuth H, et al. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med 1985;312:270-276.
5. Fujimoto Y, Hampton LL, Wirth PJ, Wang NJ, Xie JP, Thorgeirsson SS. Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas of China. Cancer Res 1994;54:281-285.
6. Paterlini P, Poussin K, Kew M, Franco D, Brechot C. Selective accumulation of the x transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology 1995;21:313-321.
7. Koike K, Nakamura Y, Kobayashi M, Takada S, Urashima T, Saigo K, Kobayashi S, et al. Hepatitis B virus DNA integration frequently observed in the hepatocellular carcinoma DNA of hepatitis C virus-infected patients. Int J Oncol 1996;8:781-784.
8. Urashima T, Saigo K, Kobayashi S, Imaseki H, Matsubara H, Koide Y, Asano T, et al. Identification of hepatitis B virus integration in hepatitis c virus-infected hepatocellular carcinoma tissues. J Hepatol 1997;26:771-778.
9. Sugawara Y, Makuuchi M, Takada K. Detection of hepatitis B virus DNA in tissues of hepatocellular carcinomas related to hepatitis C virus, which are negative for hepatitis B virus surface antigen. Scand J Gastroenterol 1999;9:934-938.
10. Zhang F, Zhu YY, Sun ZT. Universal presence of HBVX gene and its close association with hotspot mutation of p53 gene in hepatocellular carcinoma of prevalent area in China. Chin J Oncol 1998;20:18-21.
11. Sun ZT, Lu PX, Gail MH, Pee D, Zhang QN, Ming LH, Wang NJ, et al. Increased risk of hepatocellular carcinoma in male HBsAg carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology 1999;30:379-383.
12. Sun T, Chu Y. Carcinogenesis and prevention strategy of liver cancer in area of prevalence. J Cell Physiol Suppl 1984;3:39-44.
13. Sun T, Wu S, Wu Y, Chu Y. Measurement of individual aflatoxin exposure among people having different risk to primary hepatocellular carcinoma. In: Hayashi Y, Nagao M, Sugimura T, Takayama S, Tomatis L, Wattenberg LW, et al., eds. Diet, Nutrition, and Cancer. Proc 16th Int Symp of Princess Takamatsu Cancer Res Fund. Tokyo: Japanese Science Society Press, 1986;225-235.
14. Ross RK, Yuan J-M, Yu MC, Wogan GN, Qian G-S, Tu J-T, Groopman JD, et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992;339:943-946.
15. Qian G-S, Ross RK, Yu MC, Yuan J-M, Gao Y-T, Henderson BE, Wogan GN, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomark Prevent 1994;3:3-10.
16. Hsu IC, Metcalf PA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991;350:427-428.
17. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991;350:429-431.
18. Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991;338:1356-1359.
19. Kirk GD, Carmus-Randon AM, Mendy M, Goedert JJ, Merle P, Trepo C, Brechot C, et al. Ser-249 p53 mutation in plasma DNA of patients with hepatocellular carcinoma from the Gambia. JNCI 2000;92:148-153.
20. Shimizu Y, Zhu JJ, Han F, Ishikawa T, Oda H. Different frequencies of p53 codon-249 hotspot mutations in hepatocellular carcinomas in Jiangsu Province of China. Int J Cancer 1999;82:187-190.
21. Fujimoto Y, Hampton L, Luo L, Wirth PJ, Thorgeirsson SS. Low frequency of p53 gene in tumors induced by aflatoxin B1 in nonhuman primates. Cancer Res 1992;52:1044-1046.
22. Ming LH, Yuan BZ, Thorgeirsson SS, Zhu YR, Wu ZY, Sun ZT. Characteristics of high frequency 249 codon mutation of p53 gene in hepatocellular carcinoma of prevalent area of China. Chin J Oncol 1999;21:122-124.
23. Jia L, Wang XW, Harris CC. Hepatitis B virus X protein inhibits nucleotide excision repair. Int J Cancer 1999;80:875-879.
24. Elmore LW, Hancock AR, Chang SF, Wang XW, Chang S, Callahan CP, Geller DA, et al. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci U S A 1997;95:14707-14712.
25. Sohn S, Jaitovitch-Groisman I, Benlimame N, Galipeau J, Batist G, Alaoui-Jamali MA. Retroviral expression of the hepatitis B virus x gene promotes liver cell susceptibility to carcinogen-induced site specific mutagenesis. Mutat Res DNA Repair 2000;460:17-28.
26. Zhu JQ, Zhang LS, Hu X, Xiao Y, Chen JS, Xu YC, Fremy J, et al. Correlation of dietary aflatoxin B1 levels with excretion of aflatoxin M1 in human urine. Cancer Res 1987;47:1848-1852.
27. Chen Z, Root M, Pan W, Chen J, Campbell TC. Use of an improved method for analysis of urinary aflatoxin M1 in a survey of mainland China and Taiwan. Cancer Epidemiol Biomark Prevent 1977;6:523-529.
28. Chen JG, Li WG: Cancer incidence in Qidong, China 1988-1992. In: Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, eds. Cancer Incidence in Five Continents. Volume VII. Lyon: IARC Sci Publ No. 143, 1997;322-325.
29. Rao CR. Linear Statistical Inference and Its Applications. New York: Wiley, 1966:319-322.
30. Mehta C, Patel N. StatXact3 for Windows Users Manual, Chapter 13. Cambridge, MA: Cytel Software Corp., 1995.
31. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748.
32. Breslow NE, Day NE. Statistical methods in cancer research. Volume 1. The Analysis of Case-Control Studies. Lyon: IARC, 1980.
33. Hsia CC, Nakashima Y, Tabor E. Deletion mutants of the hepatitis B virus X gene in human hepatocellular carcinoma. Biochem Biophys Res Commun 1997;241:726-729.
34. Adamson RH. Induction of hepatocellular carcinoma in non-human primates by chemical carcinogens. Cancer Detect Prevent 1989;14:215-219.
35. Galibert F, Mandart E, Fitoussi F, Tiollais P, Charnay P. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature 1979;281:646-650.